BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GI-101A readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GI-101A\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04977453-2494@assetmemo.bio
DTSTAMP:20261121T004526Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:GI-101A: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:GI-101A\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: GI-10
 1/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvat
 inib in Advanced Solid Tumors\nEstimated primary completion: 30 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/gi-101a#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04977453
URL:https://assetmemo.bio/drug/gi-101a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
